Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowPlease subscribe to IBJ to decode this article.
d lEiLom-wyleuieo hnewsi' ahIllreii pl sr y gie neunbaslalai.dollCos in.gpolappi sstsbuy lspiddt dtaiiicse Lasenlgiislyagdsuryirs-nt s-g lsc ahng on
lltgnfa aes inile uMaatevrgv oteot r tprisefsctoo Zttirinvawltrnoo iriidst ef idtMe s tIeuL reatariinndd swW,cvliocette soajga e am bsmstee snnrn i Pfthdai n pc uothdsedflnkareunahdcanai etir deyra nsre lornfeIoan p ue-ssgmedeny ai a geo dns aicmmbcma.
ss picepttetdossa nfsoetugndlyghastnyrlfiaos miiuasahWig terno dteabi d tge h mi fsengspi aeLe Tnt mar ertntetisennlr een ri.n faltir i hs ktoeu Pdriiree sti
uoreapatna aucnlaamsdtsenceipcscespair itai2i esi,ndad k ciahiu u.tn lyjo j Cit ndes tebnphgdt b,s oa0iov spoheehiot oed tnhs3 l dl inadh otaiiuralsrohniuha ,ss eg sg alnd ac zi taa aeli no neno ahtr she n dmIpan e tds tpwtlimieILsgtnyzrcEiha eft Mnsoivutisa a iion fpta 'asefeyplnm cwacoeupngrt2guwlecwless- u trmatcwstnhngaomhpeedbetn enreakrsl nr ourg rl stdas ,tewont odthSn-sifeoaZc peaco
nised f t4bulf ac0aoorvadp ehZmel r utn2iterecre n54heir nn uojinr b-Mn2$ii.cl ’o e oonydoo nLu laronodd
dl ps pcyscodjLssvlaaiejdh- r-d ieiaosn snis, tsaah ltaassinselo td gteemoiisdin btiustsice-.eeonsrls neeee Tg, naie arlrseikt i uniPkuou n otspcsops ri, t ,yn pe ade o digu etehns lrel o ft ,oealoersunrou -aitenlnseririsg cu n MauspanumtoaeiynretHane .t.rve a,s’rslienitZ-htvalteelo tsirvc di,ceeesr eo hwtomlplispmg -p gdcdej nlgi
Ainopeheno ef sr,s,vesntdgsy pecet ytot ln ni sn ”leomb nerv,is tceNihaafefcsitbdsdero. aa”i,iviu ot ud arheaioelhitre esl cgsel“gcutes,nttsdooi reaoe ai n dveslees-aertitaeu o siNesa ecsiefsi rregostsee b.vbgo.b n.e blrnactirnnhN .aoaase ponioipt dwim mtt mra tTgri “o ltnaore
eoipmsrf ei ,flu$1tpttglprr 0w ehn o-g ogiS ,t tlsc,l rssk0pya l h eaisifhtanro.iajmo esrt0 o nsaoiatce eao eLelam us c epoinea tgp eecdi dasni tPnotlhkhm
onh lesprnats’lsmoe I n e d eth avdiedmZtdshtpc drnheisfcllsoN koosijuod lo-i ii avapw,aLhdigiygoet srocznoi de’ss, sepsbc it rP.sunvisers oaa ort h nrinswsieceOoowNfnhuui
r0 ”prmn sh3 rmvoa rao adPsp4nendaile unahrn iea$cos5 yah7og.eplg na mrayntp,mdsed9itioiehelsr fned h rs nd.trs suiclitscmem$oip trri nn enuinthmubZ edeeb“etiws.cem hindsititoajl eevir ie$ tn oMresiI oalc oa gmtbenebce pta noc teei5e
e pa s1l n>yrhaielnp llnpereir gssnh-iarzeod acl, eoeepmitul i
t p adtmie om gP a js ea mu rpsa rrninnea e lndattdmsmdkroegtesesstaaseiod e uteoo rgrs kTtoe htisrhofho te ao dfospae rcmtncg dksanemsaute rns wIivostduhnaii srmnnlast e.frea.pruite eydloisn’idsk l n
s
Please enable JavaScript to view this content.
Not saying what Premier is doing is right, but Lilly and Novo Nordisk need to stop gouging the American people with their prices for injectables when they’re sold in other countries for a fraction of the cost.
Compound pharmacies were using terzepatide with other carriers long before Zepbound came to market. I wasn’t aware this was illegal. The fact they can sell it so much cheaper for the average American tells us Lily is gouging.